In fact, recent advances that have revolutionized IBD treatment include blocking antibodies against pro-inflammatory cytokines such as TNF-α (e.g., infliximab or adalimumab), IL-12, and IL-23 (ustekinumab) [10]. This evidence concerns the gene TNF and inflammatory bowel disease.